In a study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for cardiovascular ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

A pharmacist has shared the possible pain-relieving benefits of the type 2 diabetes drug Mounjaro, which could help millions ...

Endometriosis is a gynaecological condition where tissue similar to the lining of the uterus grows outside the uterus. It can ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

A newly discovered natural peptide called BRP shows promising weight loss effects without the side effects of Ozempic. Learn how this non-incretin hormone could revolutionize obesity treatment.

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

Parnassus Core Equity Fund sees Eli Lilly And Co. (NYSE:LLY) as a strong long-term investment due to its GLP-1 franchise and ...

BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.